title: Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.
abstract: Immune checkpoint inhibitors (ICIs) are actually being indicated more commonly in the management of chemoresistant cancer patients in view of their favorable toxicity profile in comparison to cytotoxic chemotherapy. In this paper, we report, to our knowledge, the first case suggestive of cytokine release syndrome secondary to pembrolizumab in a patient with metastatic lung squamous cell carcinoma. In view of the quick approvals of ICI and the absence of sufficient knowledge of the corresponding toxicity profile, the occurrence of any clinical or biological sign or symptom in patients receiving ICI requires further investigation.
authors.affiliation: Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Lebanon.
authors.forename: Elie El
authors.initials: EE
authors.lastname: Rassy
authors.affiliation: Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Lebanon.
authors.forename: Tarek
authors.initials: T
authors.lastname: Assi
authors.affiliation: Department of Nephrology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Lebanon.
authors.forename: Jamale
authors.initials: J
authors.lastname: Rizkallah
authors.affiliation: Department of Hematology-Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Lebanon.
authors.forename: Joseph
authors.initials: J
authors.lastname: Kattan
mesh_terms: D000740:Anemia / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D016207:Cytokines / Q000378:metabolism; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis* / Q000517:prevention & control; D004487:Edema / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D005121:Extremities / Q000473:pathology; D005221:Fatigue / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011239:Prednisolone / Q000627:therapeutic use; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D012907:Smoking; D013577:Syndrome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D011239:Prednisolone; C582435:pembrolizumab
keywords: cytokine release syndrome; immune checkpoint inhibitors; limb edema; pembrolizumab; squamous cell lung cancer